AFL

Executive Summary

Investment Thesis

Aflac delivered a mixed Q1 2026, with total revenues of $4.3 billion (+27.9% YoY) beating estimates, while adjusted EPS of $1.75 missed consensus of $1.79 by 2.2%. Net earnings surged to $1.98 per diluted share vs. $0.05 a year ago, largely driven by investment gains rather than operating improvement.

The company's Dividend King status (44 consecutive years of increases) and aggressive capital return program ($1.3B returned in Q1 alone, including $1.0B in buybacks) underpin the income-oriented investment thesis. The 5.2% dividend increase to $0.61/quarter signals continued management confidence. With a payout ratio of just 32.9%, there is substantial runway for future increases.

However, structural headwinds persist: Japan net premiums continue their multi-year decline as the supplemental insurance market matures, and currency risk from the yen/dollar exchange rate creates earnings volatility. The stock trades at 2.15x book value, above its 5-year average of ~1.8x, and near its 52-week high of $119.81, leaving limited margin of safety.

Verdict: Aflac is a high-quality income compounder best suited for dividend-focused portfolios, but at current prices the total return potential is limited. Hold with a probability-weighted 12-month target of $120. Accumulate on pullbacks below $110 for better risk-adjusted entry.

Growth Drivers

Key Growth Catalysts

$1.3B Returned to Shareholders in Q1 2026

Capital Return Machine

Aflac repurchased $1.0B in shares and paid $315M in dividends in Q1 alone. At this pace, annual capital returns exceed $5B, reducing share count by ~3-4% annually. This financial engineering drives EPS growth even when operating earnings are flat.

#1 Cancer Insurance Provider in Japan

Aflac Japan Cancer Insurance Franchise

Aflac insures 1 in 4 Japanese households. The cancer insurance franchise generates high-margin, sticky premium income with minimal lapse rates. While new policy sales face headwinds from aging demographics, the in-force block provides decades of predictable cash flow.

Growing U.S. Supplemental Benefits Platform

U.S. Group Benefits Expansion

Aflac U.S. is expanding distribution through group voluntary benefits, worksite marketing, and digital enrollment platforms. The U.S. segment provides geographic diversification and growth optionality beyond the mature Japan market. Network dental and vision products add new revenue streams.

2026-04-29

Q1 2026 Earnings Release

Revenue $4.3B (+27.9% YoY), net EPS $1.98, adj. EPS $1.75 (missed $1.79 est.). Returned $1.3B to shareholders. Board approved 5.2% dividend increase to $0.61/quarter.

2026-05-20

Quarterly Dividend Ex-Date

Ex-dividend date for $0.61/share quarterly dividend. Payment date June 1, 2026. Annual yield of 2.06% at current price.

2026-07-29

Q2 2026 Earnings (est.)

Consensus expects revenue ~$4.1B and adj. EPS ~$1.85. Key watch: Japan net premium trends, yen/dollar rate impact, and investment income trajectory.

2026-10-28

Q3 2026 Earnings (est.)

Focus on full-year guidance trajectory. Japan cancer insurance sales trends and U.S. group benefits enrollment season results will be critical.

2027-02-03

Q4 2026 / FY2026 Earnings (est.)

Full-year results and 2027 outlook. Expect 45th consecutive dividend increase announcement. Buyback authorization renewal likely.

Peer Comparison

Relative Valuation vs. Competitors

Company	price	marketCap	revenueTTM	revenueGrowth	forwardPE	evRevenue
Aflac Incorporated	118.41	60.2B	17.0B	3%	15.6	1.8
MetLife Inc.	88.5	58.2B	72.5B	5%	9.8	0.6
Unum Group	78.2	13.8B	12.8B	4%	8.2	0.9
Prudential Financial	125.4	45.6B	75.3B	6%	10.5	0.5
Globe Life Inc.	115.6	10.2B	6.1B	7%	11.4	1.5

AFL commands the highest P/E and P/B among life/health insurance peers, justified by its superior ROE (16.4% vs peer avg ~12%), Dividend King status, and Japan monopoly moat. However, MetLife and Unum offer higher dividend yields at lower valuations. PRU is the pure yield play at 4.15%. For total return, AFL's premium valuation requires Japan stabilization to sustain.

Valuation

Price Targets & Scenarios

Scenario	Price Target	Assumptions	Probability
Bull Case	$140	Japan insurance market stabilizes; yen strengthens 5-10% vs. USD; U.S. group benefits growth accelerates to double digits; investment income expands on higher rates; buyback pace maintained at $4B+ annually. Multiple re-rates to 2.5x book.	20%
Base Case	$120	Steady-state supplemental insurance demand in Japan with gradual premium erosion. U.S. business grows mid-single digits. Adjusted EPS of $7.45 in FY26, growing 6% in FY27. Dividend increased 5-6% annually. P/E stabilizes at 15-16x forward.	55%
Bear Case	$90	Yen depreciates sharply (>10%); Japan net premiums decline accelerates; credit losses in investment portfolio; U.S. competition intensifies from MetLife/Unum; interest rate cuts compress investment yields. Multiple compresses to 11-12x forward earnings.	25%

Analyst Consensus

Goldman Sachs

UBS

Argus Research

Raymond James

2 Buy, 7 Hold, 2 Sell

Risk & Ownership

Risk Assessment & Insider Signals

!Risk Factors

Japan Yen/Dollar Currency Volatility: Aflac Japan represents ~70% of earnings. A 10% yen depreciation vs. USD reduces translated earnings by approximately $0.50-$0.70 per share. BOJ policy normalization could go either direction, creating persistent two-way risk.
Japan Net Premium Decline: Japan supplemental insurance market is mature and shrinking. Aging demographics, saturated cancer insurance penetration, and competition from Japan Post and domestic insurers are eroding net premiums. This structural headwind limits organic top-line growth.
Investment Portfolio Credit Risk: Aflac manages a $95.8B investment portfolio concentrated in Japanese government bonds, U.S. corporates, and yen-denominated assets. Rising defaults or a credit crunch could produce significant realized losses, as occurred during the 2008-2009 financial crisis.
Interest Rate Sensitivity: While higher rates boost new money yields, they also reduce the market value of existing bond holdings and can slow policy sales. A rapid rate cut cycle would compress net investment income, pressuring EPS growth.
U.S. Competitive Intensity: MetLife, Unum, and other supplemental benefits providers are aggressively expanding worksite marketing. Digital-first insurtech competitors are targeting Aflac's core voluntary benefits market with lower-cost distribution models.
Regulatory and Tax Risk: Changes to Japanese insurance regulations, U.S. tax treatment of foreign-source income, or NAIC capital requirements could adversely impact profitability or capital allocation flexibility.

OOwnership & Insider Signals

Vanguard Group: 11.0% | 56.6M shares | Institutional
Japan Post Holdings: 10.0% | 51.5M shares | Strategic
BlackRock Inc: 7.4% | 38.1M shares | Institutional
State Street Corp: 4.8% | 24.7M shares | Institutional
J&A Alliance Trust (Amos Family): ~20% voting power | 51.6M shares | Insider/Strategic
Other Institutional: 35.8% | ~184M shares | Institutional

Recommendation

Summary

Price

$118.41

12mo Target

$120 (weighted)

Upside

+1.3%

Rating

Hold

Div Yield

2.06%

Forward P/E

15.6x

Entry Strategy

50%

$110-$113

Buy near 50-DMA support ($113) where dividend yield expands to ~2.2% and risk/reward is most favorable.

35%

$105-$107

Add near 200-DMA ($106) on macro or earnings-driven selloff. Yield above 2.3% with strong technical support.

15%

$100-$103

Reserve for deep correction near 52-week lows. Yield above 2.4% with maximum margin of safety.

Investment Thesis

Performance Snapshot — Insurance / Dividend King

Quarterly Revenue Trend

Key Growth Catalysts

Forward Estimates, Surprises & Insider Activity

Forward Earnings Estimates

Earnings Surprise Track Record

Insider Activity (90 Days)